Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B

Journal of Clinical Virology

Volumn 52, Issue 3, 2011, Pages 204-209

  Farnik, Harald ^a   Lange, Christian Markus ^a,b   Hofmann, Wolf Peter ^a   Berger, Annemarie ^a   Allwinn, Regina ^a   Welker, Martin Walter ^a   Trojan, Jörg ^a   Sarrazin, Christoph ^a   Herrmann, Eva ^a   Zeuzem, Stefan ^a   Kronenberger, Bernd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Apoptosis; Hepatitis B; Necrosis; Nucleoside analogue

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKERATIN 18; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC HEPATITIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MALE; NECROSIS; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; APOPTOSIS; DISEASE PROGRESSION; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KERATIN-18; MALE; NECROSIS; NUCLEOSIDES; NUCLEOTIDES;

EID: 80054707315     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.08.009     Document Type: Article

References (22)

1. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
2. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49:S45-S55.
3. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
4. Kronenberger B., Zeuzem S., Sarrazin C., Mihm U., von Wagner M., Hofmann W.P., et al. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir Ther 2007, 12:779-787.
5. Kronenberger B., Wagner M., Herrmann E., Mihm U., Piiper A., Sarrazin C., et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat 2005, 12:307-314.
6. Hotchkiss R.S., Strasser A., McDunn J.E., Swanson P.E. Cell death. N Engl J Med 2009, 361:1570-1583.
7. Colombo M. Does chemotherapy prevent HBV-related hepatocellular carcinoma?. Cons Dig Liver Dis 2010, 42(Suppl. 3):S298-S301.
8. Liaw Y.F. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 2011, 31(Suppl. 1):117-121.
9. Iavarone M., Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis 2011, 43(Suppl. 1):S32-S39.
10. Lok A.S. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?. J Gastroenterol Hepatol 2011, 26:221-227.
11. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
12. Takkenberg R.B., Zaaijer H.L., Molenkamp R., Menting S., Terpstra V., Weegink C.J., et al. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. J Med Virol 2009, 81:988-995.
13. Jochum C., Gieseler R.K., Gawlista I., Fiedler A., Manka P., Saner F.H., et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009, 80:235-240.
14. Muhlbacher A., Weber B., Burgisser P., Eiras A., Cabrera J., Louisirirotchanakul S., et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008, 197:55-64.
15. Calabrese F., Pontisso P., Pettenazzo E., Benvegnu L., Vario A., Chemello L., et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000, 31:1153-1159.
16. Bantel H., Lugering A., Heidemann J., Volkmann X., Poremba C., Strassburg C.P., et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004, 40:1078-1087.
17. Bantel H., Lugering A., Poremba C., Lugering N., Held J., Domschke W., et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001, 34:758-767.
18. Jaroszewicz J., Calle S.B., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
19. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
20. Volz T., Lutgehetmann M., Wachtler P., Jacob A., Quaas A., Murray J.M., et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007, 133:843-852.
21. Cai W., Xie Q., An B., Wang H., Zhou X., Zhao G., et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010, 48:22-26.
22. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.